Nimacimab
CBeyond
Skye Bioscience · Phase 2 · Active, not recruiting · Enrollment 136
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Nimacimab injection | n/r | n/r | n/r | n/r | n/r |
| Nimacimab placebo injection | n/r | n/r | n/r | n/r | n/r |
| Semaglutide injection + Nimacimab injection 200 mg | n/r | n/r | n/r | n/r | n/r |
| Semaglutide injection + Nimacimab placebo injection | n/r | n/r | n/r | n/r | n/r |
| Open-label 300 mg Nimacimab injection (study extension) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.